Askorbatna kiselina za liječenje Charcot‐Marie‐Tooth bolesti
Información
- DOI:
- https://doi.org/10.1002/14651858.CD011952Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 11 diciembre 2015see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Neuromuscular
- Copyright:
-
- Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
B Gess wrote the first and all subsequent drafts. P Young and D Pareyson commented on the first and subsequent drafts. MM Reilly commented on the penultimate draft. P Young, M Reilly and D Pareyson assisted B Gess in the selection of studies. B Gess and J Baets independently extracted data from the studies. P Young assisted in evaluation of data and studies and overlooked the progress of the review. M Reilly supported the progress of the review. P de Jonghe assisted J Baets in extraction of data. B Gess analysed the data. All six authors agreed to the final text.
Sources of support
Internal sources
-
University of Münster, Germany.
-
University of Antwerp, Belgium.
External sources
-
European Neuromuscular Centre, Netherlands.
Declarations of interest
MM Reilly and D Pareyson were involved as investigators in one of the trials included in this review (Pareyson 2011). B Gess and P Young have been involved in basic research projects on the function of ascorbic acid in the peripheral nervous system (Gess 2010; Gess 2011).
Acknowledgements
We thank the Trials Search Co‐ordinator of the Cochrane Neuromuscular Disease Group, Angela Gunn, who provided the searches. We also thank Ruth Brassington of the Cochrane Foundation Neuromuscular Study Group for her excellent assistance with formal requirements and her much appreciated draft of the plain language summary.
This project was supported by the National Institute for Health Research (NIHR) via Cochrane Infrastructure funding to the Cochrane Neuromuscular Disease Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service or the Department of Health. The Cochrane Neuromuscular Disease Group is also supported by the MRC Centre for Neuromuscular Diseases.
Version history
| Published | Title | Stage | Authors | Version |
| 2015 Dec 11 | Ascorbic acid for the treatment of Charcot‐Marie‐Tooth disease | Review | Burkhard Gess, Jonathan Baets, Peter De Jonghe, Mary M Reilly, Davide Pareyson, Peter Young | |
Differences between protocol and review
B Gess, J Baets, MM Reilly and D Pareyson joined the author team for this review. F Stögbauer and T Butterfass‐Bahloul, who were authors of Young 2008, withdrew.
We added additional sections to the Methods according to current Cochrane requirements.
The time points of 12 and 24 months for our meta‐analyses were chosen post hoc, because we found that trials used either a 12‐month or a 24‐month study duration and these time points are more suitable than 12 weeks, given the slow progression of the disease.
'Explicit inclusion criteria' relate to the GRADE criterion of indirectness. We removed it from the 'Risk of bias' assessment.
Notes
The review 'Treatment for Charcot Marie Tooth disease' (Young 2008) has been split into two separate reviews: Ascorbic acid for Charcot‐Marie‐Tooth disease and Treatments other than ascorbic acid for Charcot‐Marie‐Tooth disease. Treatments other than ascorbic acid for Charcot‐Marie‐Tooth disease will be published shortly.
